> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Repligen Lifts 2026 Revenue Outlook To $844 Million-$852 Million, Yet A $41.2 Million Writedown Drives A Quarterly Loss
- URL: https://www.bullished.co/repligen-lifts-2026-revenue-outlook-to-844-million-852-million-yet-a-41-2-million-0a3c1ffb/
- Published: 2026-10-27T11:17:17.000Z
- Updated: 2026-10-28T16:19:23.000Z
- Description: Adjusted earnings rose to $0.53 a share in the third quarter, while standard accounting shows a $0.68 per-share loss.
- Author: Matteo Parrino
- Tags: Earnings, RGEN, Industry: Healthcare

[Repligen](https://www.bullished.co/tag/rgen/), which makes the filtration, chromatography and analytics products biopharmaceutical companies use to manufacture biologic drugs, raised its 2026 revenue forecast to [$844 million to $852 million](https://www.sec.gov/Archives/edgar/data/0000730272/000162828026067405/rgen-20261027xexx991.htm?ref=bullished.co) in an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Tuesday. The same report showed a third-quarter net loss of $38.4 million, or $0.68 a share, after a $41.2 million intangible asset impairment.

## Sales up, standard earnings under

Third-quarter revenue was $209.3 million, up 11% as reported and 12.5% organic from $188.8 million a year earlier. CEO Olivier Loeillot called it "a record third quarter."

Under standard accounting, the company lost $29.5 million from operations, against $16.8 million of operating income a year earlier. Net income swung to the $38.4 million loss from $14.9 million of profit, and the loss per share compares with $0.26 of earnings in the prior-year quarter.

On the company's adjusted basis, which excludes the impairment among other items, operating income rose to $33.3 million from $26.8 million. Adjusted earnings per share were $0.53, up from $0.46, and adjusted operating margin reached 15.9% from 14.2%.

## The BioLife addition and the new guidance

Repligen closed its BioLife Solutions acquisition on October 6\. The company says it adds a cell therapy consumables platform with recurring revenue, and Loeillot said integration is progressing well and the company has already acted on a sizable portion of expected operating expense synergies.

Full-year guidance includes BioLife from the closing date. It implies reported growth of 14.5% to 15.5% and organic growth of 12% to 13%, with adjusted earnings per share of $2.05 to $2.09\. About 2.5 points of the reported growth come from acquisitions, mainly BioLife, net of the sale of Polymem.

The company also guides to adjusted operating income of $135 million to $139 million.

## Cash pile and the nine-month picture

Cash, cash equivalents and marketable securities stood at $863 million at September 30, against $768 million at the end of 2025\. For the first nine months, the company booked a $13.7 million loss on the sale of a business, and its net loss was $25.1 million, against a $35.6 million profit a year earlier.

Repligen is scheduled to discuss the results, BioLife integration and the outlook on a call at 8:00 a.m. ET Tuesday.

Adjusted nine-month earnings per share stand at $1.55 against $1.23 a year earlier, while the standard-accounting figure is a loss of $0.44.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — REPLIGEN CORP (RGEN)](https://www.sec.gov/Archives/edgar/data/0000730272/000162828026067405/rgen-20261027.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit rgen-20261027xexx991.htm — REPLIGEN CORP 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000730272/000162828026067405/rgen-20261027xexx991.htm?ref=bullished.co) — SEC EDGAR

### More on Repligen

- [Repligen Says BioLife Deal Puts 2027 Revenue Above $1 Billion, But Calls It Not Formal Guidance](https://www.bullished.co/repligen-says-biolife-deal-puts-2027-revenue-above-1-billion-but-calls-it-not-formal-01990904/)
- [Repligen CEO Says Equipment 'Tap' Is Only 5-10% Open, Even After Five-Year High In Orders](https://www.bullished.co/repligen-ceo-says-equipment-tap-is-only-5-10-open-even-after-five-year-high-in-orders-cd78f39d/)
- [Repligen Closes BioLife Deal: $11.25 In Cash And 0.1442 Repligen Shares For Each BioLife Share](https://www.bullished.co/repligen-closes-biolife-deal-11-25-in-cash-and-0-1442-repligen-shares-for-each-biolife-1a5d37a5/)

[All Repligen (RGEN) coverage →](https://www.bullished.co/tag/rgen/)